Mitoxantrone in advanced renal cancer: a phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group. 1984

A T van Oosterom, and S D Fosså, and G Pizzocaro, and J P Bergerat, and A V Bono, and M De Pauw, and R Sylvester

Mitoxantrone at a dose of 15 mg/m2 i.v. q 3 weeks failed to produce responses in 29 adequately treated patients with measurable advanced renal cell carcinoma. The side-effects observed in this group of patients with a good performance status were generally mild. On the basis of this negative result, the application of mitoxantrone in this disease is not recommended.

UI MeSH Term Description Entries
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008942 Mitoxantrone An anthracenedione-derived antineoplastic agent. Mitozantrone,CL-232325,DHAQ,Mitoxantrone Acetate,Mitoxantrone Hydrochloride,Mitroxone,NSC-279836,NSC-287836,NSC-299195,NSC-301739,NSC-301739D,Novantron,Novantrone,Onkotrone,Pralifan,Ralenova,Acetate, Mitoxantrone,CL 232325,CL232325,Hydrochloride, Mitoxantrone,NSC 279836,NSC 287836,NSC 299195,NSC 301739,NSC 301739D,NSC279836,NSC287836,NSC299195,NSC301739,NSC301739D
D002292 Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. Adenocarcinoma, Renal Cell,Carcinoma, Hypernephroid,Grawitz Tumor,Hypernephroma,Renal Carcinoma,Adenocarcinoma Of Kidney,Adenocarcinoma, Renal,Chromophil Renal Cell Carcinoma,Chromophobe Renal Cell Carcinoma,Clear Cell Renal Carcinoma,Clear Cell Renal Cell Carcinoma,Collecting Duct Carcinoma,Collecting Duct Carcinoma (Kidney),Collecting Duct Carcinoma of the Kidney,Nephroid Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Cancer,Renal Cell Carcinoma,Renal Cell Carcinoma, Papillary,Renal Collecting Duct Carcinoma,Sarcomatoid Renal Cell Carcinoma,Adenocarcinoma Of Kidneys,Adenocarcinomas, Renal Cell,Cancer, Renal Cell,Carcinoma, Collecting Duct,Carcinoma, Collecting Duct (Kidney),Carcinoma, Nephroid,Carcinoma, Renal,Carcinomas, Collecting Duct,Carcinomas, Collecting Duct (Kidney),Carcinomas, Renal Cell,Collecting Duct Carcinomas,Collecting Duct Carcinomas (Kidney),Hypernephroid Carcinoma,Hypernephroid Carcinomas,Hypernephromas,Kidney, Adenocarcinoma Of,Nephroid Carcinomas,Renal Adenocarcinoma,Renal Adenocarcinomas,Renal Carcinomas,Renal Cell Adenocarcinoma,Renal Cell Adenocarcinomas,Renal Cell Cancers,Renal Cell Carcinomas,Tumor, Grawitz
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

A T van Oosterom, and S D Fosså, and G Pizzocaro, and J P Bergerat, and A V Bono, and M De Pauw, and R Sylvester
December 1989, European journal of cancer & clinical oncology,
A T van Oosterom, and S D Fosså, and G Pizzocaro, and J P Bergerat, and A V Bono, and M De Pauw, and R Sylvester
August 1989, European journal of cancer & clinical oncology,
A T van Oosterom, and S D Fosså, and G Pizzocaro, and J P Bergerat, and A V Bono, and M De Pauw, and R Sylvester
January 1990, European journal of cancer (Oxford, England : 1990),
A T van Oosterom, and S D Fosså, and G Pizzocaro, and J P Bergerat, and A V Bono, and M De Pauw, and R Sylvester
January 1992, European journal of cancer (Oxford, England : 1990),
A T van Oosterom, and S D Fosså, and G Pizzocaro, and J P Bergerat, and A V Bono, and M De Pauw, and R Sylvester
January 1988, Progress in clinical and biological research,
A T van Oosterom, and S D Fosså, and G Pizzocaro, and J P Bergerat, and A V Bono, and M De Pauw, and R Sylvester
January 1995, British journal of cancer,
A T van Oosterom, and S D Fosså, and G Pizzocaro, and J P Bergerat, and A V Bono, and M De Pauw, and R Sylvester
January 1998, European urology,
A T van Oosterom, and S D Fosså, and G Pizzocaro, and J P Bergerat, and A V Bono, and M De Pauw, and R Sylvester
April 1999, European urology,
A T van Oosterom, and S D Fosså, and G Pizzocaro, and J P Bergerat, and A V Bono, and M De Pauw, and R Sylvester
August 1988, European journal of cancer & clinical oncology,
A T van Oosterom, and S D Fosså, and G Pizzocaro, and J P Bergerat, and A V Bono, and M De Pauw, and R Sylvester
January 1993, European journal of cancer (Oxford, England : 1990),
Copied contents to your clipboard!